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ABSTRACT
We previously identified miR-4731-5p (miR-4731) as a melanoma-enriched 
microRNA following comparison of melanoma with other cell lines from solid 
malignancies. Additionally, miR-4731 has been found in serum from melanoma 
patients and expressed less abundantly in metastatic melanoma tissues from stage 
IV patients relative to stage III patients. As miR-4731 has no known function, we 
used biotin-labelled miRNA duplex pull-down to identify binding targets of miR-
4731 in three melanoma cell lines (HT144, MM96L and MM253). Using the miRanda 
miRNA binding algorithm, all pulled-down transcripts common to the three cell lines 
(n=1092) had potential to be targets of miR-4731 and gene-set enrichment analysis of 
these (via STRING v9.1) highlighted significantly associated genes related to the ‘cell 
cycle’ pathway and the ‘melanosome’. Following miR-4731 overexpression, a selection 
(n=81) of pull-down transcripts underwent validation using a custom qRT-PCR array. 
These data revealed that miR-4731 regulates multiple genes associated with the 
cell cycle (e.g. CCNA2, ORC5L, and PCNA) and the melanosome (e.g. RAB7A, CTSD, 
and GNA13). Furthermore, members of the synovial sarcoma X breakpoint family 
(SSX) (melanoma growth promoters) were also down-regulated (e.g. SSX2, SSX4, and 
SSX4B) as a result of miR-4731 overexpression. Moreover, this down-regulation of 
mRNA expression resulted in ablation or reduction of SSX4 protein, which, in keeping 
with previous studies, resulted in loss of 2D colony formation. We therefore speculate 
that loss of miR-4731 expression in stage IV patient tumours supports melanoma 
growth by, in part; reducing its regulatory control of SSX expression levels.
INTRODUCTION
In our previous study, miR-4731-5p (miR-4731) 
was identified as a melanoma-enriched (mean 24-fold; 
P(cor)=1.47E-04) miRNA following a comprehensive 
analysis of a large panel of melanoma cell lines (expressed 
in 37/55) in comparison with other cell lines derived from 
solid malignancies (expressed in 5/34) [1]. In a separate 
study, we also found miR-4731 to be down-regulated (23-
fold mean; P(cor)=0.004) in metastatic melanoma spread 
to distant sites (stage IV) compared with loco-regional 
metastases (stage III) [2]. Moreover, together with the 
expression of another miRNA (miR-204), miR-4731 was 
able to distinguish stage III from stage IV tumours with 
high sensitivity and specificity (AUC=0.89; p=0.003, 
OR=3.0, CI 1.45-6.2) [2].
miR-4731 is located at chr17p12 (chr17:15,154,944-
15,155,013) in an intron (>5 kb from intron-exon border) 
of the peripheral myelin protein 22 gene (PMP22), which 
is commonly associated with hereditary Charcot-Marie-
Tooth disease type 1A (CMT1A). PMP22 is expressed 
primarily in neural crest derived cell lineages (including 
melanocytes), however expression of PMP22 has also 
been associated with cell proliferation and survival in 
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breast cancer [3–5]. To date no target genes of miR-4731 
have been functionally validated.
Given the association of miR-4731 with melanoma 
in our previous studies, we sought to identify the genes 
regulated by this miRNA. We employed the optimised 
biotin-labelled miRNA duplex pull-down procedure [1, 
6, 7] to identify binding targets of miR-4731, followed 
by gene-set enrichment analysis (GSEA) to help elucidate 
significant pathways and biological processes regulated 
by miR-4731. A selection of pull-down target genes 
(n=81) underwent validation via qRT-PCR following 
over-expression of a miR-4731 mimic in three melanoma 
cell lines. We report here that miR-4731 has the potential 
to regulate multiple genes involved in the cell cycle and 
the melanosome. Importantly, overexpression of miR-
4731 inhibits SSX4 protein (pull-down target) resulting 
in a marked reduction in 2D colony formation in 3/3 
melanoma cell lines.
RESULTS AND DISCUSSION
The verification of miR-4731 as a melanoma-
enriched miRNA
miR-4731 was identified following a comprehensive 
miRNA microarray (miRBase v18) analysis of a panel 
of melanoma cell lines (n=55) compared with other 
solid malignancies (n=34) [1]. In the current study, the 
microarray expression data for miR-4731 was validated 
using qRT-PCR in an extended panel of cell lines derived 
from melanoma (n=100; including 55 that were initially 
assayed) and other solid cancers (n=34) (Supplementary 
Table S1). The mean expression level of miR-4731 is 
significantly higher (Mann-Whitney U-test; P≤0.0001) 
in melanomas compared to other cancers (Figure 1). The 
expression of PMP22 (miR-4731 host gene) was assessed 
in relation to that of miR-4731 to identify any correlations. 
In 14/43 (32%) melanoma cell lines with no detectable 
miR-4731 expression, PMP22 was expressed above 
background (data not shown). This is suggestive that miR-
4731 is not under the same transcriptional control as its 
host gene and is independently regulated. In the remaining 
samples (29/43), there was an inverse correlation observed 
(Pearson’s R2= -0.25) which suggests that expression of 
PMP22 may be negatively regulated by miR-4731 (data 
not shown).
Target gene identification via biotin-labelled 
miRNA duplex ‘pull-down’ of mRNA transcripts
To identify genes potentially regulated by miR-4731, 
we used the unbiased biotin-labelled pull-down procedure 
[1, 6, 7], which harnesses the conventional AGO2-directed 
binding of the mature miRNA to the mRNA transcript. 
By modifying the miRNA sequence with a biotin label, 
miRNA:mRNA bound transcripts can be ‘pulled-down’ 
using streptavidin-coated magnetic beads. This procedure 
was applied to three melanoma cell lines (HT144, MM96L 
and MM253), chosen based on their low, yet detectable 
endogenous expression of miR-4731, together with 
transfection ability. As we were looking for enrichment of 
biotin-labelled transcripts, we only considered transcripts 
that were up-regulated in each sample compared to the 
biotin-labelled negative control (Neg-Scr) (see Materials 
and Methods). There were numerous targets (887-2496 
transcripts) specific to each cell line, likely due to inherent 
differences between them, such as global gene expression 
profiles and mutational background. Due to these 
differences we focussed on common transcripts between 
all three cell lines (Supplementary Figure S1). Obsolete 
and duplicate transcripts were removed, which left 1154 
unique transcripts (Supplementary Table S2) representing 
1092 different genes (see Materials and Methods).
Verification of ‘pulled-down’ genes using 
prediction algorithms
Full-length (5' UTR, protein coding sequence, and 3' 
UTR) FASTA sequences were collated for each transcript 
(n=1154) and parsed through the prediction algorithm 
miRanda-3.3a (see Materials and Methods). All pulled-
down transcripts were predicted to be targets of miR-4731 
by the program when the binding threshold was set at 100 
(data not shown). However by reducing the stringency 
threshold, the algorithm may allow for an increased 
number of false positives. The reduced threshold was 
used to highlight that miR-4731 had the capacity to bind 
to the transcript given the right biological conditions. It is 
interesting to note that when the miRanda algorithm was 
instructed to only call ‘seed’ binding occurrences, believed 
to be the most common binding type, 505/1154 (44%) 
transcripts were called. Therefore, the majority of the pull-
down (PD) transcripts had a mixture of ‘non-seed’ binding 
present (e.g. centred, 3' supplementary, and bulged sites 
[8–10]), which indicates that there was no bias toward 
particular sites based on fold enrichment. This observation 
may in part be explained by experimental bias previously 
observed with this procedure [6], that the biotin tag on the 
synthetic miRNA duplexes may actually prevent their 3' 
end from binding to AGO [6]. It is believed that the biotin-
labelled miRNAs interact more readily with mRNAs and 
alleviate the reliance on ‘seed’ binding from the 5' end 
[6]. We found that 44% of binding sites can be attributed 
to seed binding, which compares well to a previous 
estimate of 41% [6]. As previously mentioned, miRanda 
3.3a was used to confirm the binding of the PD transcripts 
using a lower stringency threshold score (100) but if 
stringent default settings were used, (binding threshold 
=140) only 668/1154 (58%) of transcripts were called. 
Other commonly used prediction programs (with default 
parameters applied) performed poorly when compared to 
the PD transcripts and miRanda 3.3a; TargetScan (27%), 
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TargetMiner (23%), DIANA-microT-CDS (19%), and 
miRDB (2%). In the absence of extensive data confirming 
the specificity of the interactions predicted by miRanda 
(which was not the focus of this study) we cannot conclude 
that miRanda is better than the other predictive programs, 
however it does highlight that multiple algorithms need to 
be assessed and functional studies need to be performed to 
validate these findings. On the other hand, the discrepancy 
observed between the PD transcripts and the prediction 
algorithms may be due to a high number of false-positives 
present in the dataset. It has been previously observed that 
a proportion of PD transcripts may arise via non-specific 
interaction with the magnetic streptavidin beads, or by 
association with endogenous biotin, and not the intended 
biotinylated miRNA [6]. However, as all PD transcripts 
were compared to those generated using a negative, 
scrambled sequence, we have reduced the occurrences of 
false positive PD transcripts, but their presence cannot be 
completely eliminated.
Network analysis reveals enrichment for key 
signalling pathways and gene ontology terms
It is widely accepted that a single miRNA has the 
potential to regulate a multitude of signalling pathways, 
achieved by the direct targeting of individual genes, 
which in turn elicit their function on their next interacting 
partner. The understanding of a miRNA’s target gene(s) is 
not only important for understanding their contribution to 
the disease process, it is crucial when it comes to utilizing 
miRNAs as therapeutic agents [11]. Rather than individual 
mRNA:miRNA pairings in a signalling pathway, many 
genes within a pathway/process may undergo regulation 
by a single miRNA (or cluster).
Of the miR-4731 PD transcripts, we postulated that 
these genes were not simply randomly selected by the 
miRNA but may actually form a network of interactions 
with each other. In steps to identify interacting partners 
contained within our dataset, we used the network analysis 
program STRING (v9.1) [12] which identifies known 
and predicted protein-protein interactions. Using default 
settings, there were a vast number of interactions (n=4225), 
with many genes being involved in >1 connection 
(visualised in Figure 2). To identify the significance of these 
interactions, gene-set enrichment analysis (GSEA) was next 
used to identify statistically (corrected Bonferroni P-values; 
see Materials and Methods) significant pathways (KEGG) 
and Gene Ontology (GO) terms. The top three KEGG 
pathways of note were related to ‘Metabolic pathways’ 
(109 genes; P(cor)=8.94E-11) the ‘Cell cycle’ (25 genes; 
P(cor)=9.24E-08) and ‘Oxidative phosphorylation’ (22 
genes; P(cor)=3.98E-05) (Supplementary Table S3). 
Figure 1: miR-4731-5p expression is significantly (Mann-Whitney U-test; ****= P≤0.0001) associated with melanoma 
cell lines as compared to other solid cancers. ΔCT values are plotted following comparison with endogenous levels of RNU6 
assessed in each sample. Error bars represent one SD from the mean.
Oncotarget49680www.impactjournals.com/oncotarget
Notably, of particular relevance to the melanocytic lineage, 
was the GO term ‘Melanosomes’ (Supplementary Table S3), 
consisting of 22 miR-4731 target genes (P(cor)=3.15E-07).
Overexpression of a miR-4731 mimic and 
regulation of pull-down transcripts
Given that 1154 transcripts (1092 genes) were 
common to all 3 melanoma cell lines, it was not feasible 
to validate all of these genes via reporter assays, qRT-
PCR or Western blotting. We did however assess 81 (7%) 
transcripts (Supplementary Table S4) using a custom 
qRT-PCR array (QIAGEN). The criteria for transcript 
selection are detailed in the Materials and Methods but 
can be summarised as follows: 1) the host gene of miR-
4731, PMP22 was selected to confirm if it was under 
transcriptional control of miR-4731; 2) all genes that had 
≥2 fold enrichment in 3/3 cell lines (n=37); 3) significant 
pathways were selected based upon a priori relevance to 
melanoma (selected pathways were ‘cell cycle’, ‘oxidation 
phosphorylation’, and ‘melanosomes’). These pathways 
had further restrictions imposed in an attempt to be more 
stringent (n=43) (see Materials and Methods). We over-
expressed a miR-4731 mimic or a negative control mimic 
(Neg-scr), in the same melanoma cell lines (HT144, 
MM96L and MM253) that were used to perform the pull-
Figure 2: Visualisation of the numerous protein-protein network connections observed after STRING analysis (larger 
font indicates genes with the most interactions with others in the geneset) and following subsequent enriched analysis, 
significant (corrected P≤0.05) pathways and GO terms were identified.
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down procedure. Supplementary Figure S2 highlights 
that a consistent over-expression was achieved in all cell 
lines tested. After a 72 hr transfection, subsequent qRT-
PCR revealed that PMP22 (miR-4731 host gene) was 
downregulated (1.4-2.2 fold) in 3/3 cell lines upon miR-
4731 overexpression (Supplementary Table S4). These 
data support the previously observed inverse correlation 
between expression levels of PMP22 and miR-4731. 
All other validated target genes related to ‘cell cycle’, 
‘oxidative phosphorylation’, and ‘melanosomes’ can be 
found in Supplementary Table S4 and summarised in 
Supplementary Table S5: those that were down regulated 
in 3/3 (n=19), 2/3 (n=12) and 1/3 (n=19); both up and 
down regulated (n=5); up regulated (n=5); and not 
observably changed at the mRNA level (≤1.2 fold up or 
down regulated) (n=21). These data provide validation 
of the binding effect of miR-4731 to up to 74% of the 
assessed transcripts. The 26% (21/81) of transcripts that 
were not observably changed at the mRNA level may 
be false positives. To confirm the absolute effect on the 
target genes, assessment at the protein level must occur to 
confirm these findings.
Key members of the melanosome and cell cycle 
pathways are regulated by miR-4731
Melanosome-related genes
In melanocytes, a melanosome’s primary purpose 
is to package and deliver melanin to keratinocytes [13]. 
A total of 11/13 genes showed differential expression 
by ≥1.3 fold in ≥1/3 cell lines (Supplementary Table 
S4). The binding of miRNAs to mRNA transcripts 
commonly results in down-regulation of the transcript; 
however up-regulation is also possible. Interestingly, 
the overexpression of miR-4731 caused both an 
up- (MM253 and HT144) and down-regulation 
(MM96L) of the assessed transcripts to be observed 
(Supplementary Table S4). For example, in relation 
to melanoma, the up-regulation of CTSD (cathepsin 
D) has been suggested to be involved in the malignant 
transformation and progression of melanocytic tumors 
[14]. RAB7A was also found to be both up- (MM253) 
and down-regulated (MM96L) upon overexpression 
of miR-4731 (Supplementary Table S4). RAB7A (a 
member of the RAS oncogene family) has recently been 
shown to control melanoma progression and the effect 
of RAB7A is known to be gene dosage dependent [15]. 
To further support the effect of miR-4731 expression 
these melanosome-related genes, we next assessed the 
expression of other key members of this process (FSCN1, 
MLPH, RAB27A, and TYR). Given these melanosome-
related genes were not present in the pull-down data, any 
observed expression differences as a result of miR-4731 
overexpression must be considered as an indirect effect. 
Nevertheless, FSCN1, MLPH, RAB27A, and TYR all 
showed fold changes ≥1.3 fold in 1/3 (FSCN1) and 2/3 
(MLPH, RAB27A, and TYR) cell lines (Supplementary 
Table S6). These additional data strengthen the 
association of the other confirmed melanosome-related 
genes (Supplementary Table S4). The highest observed 
fold changes were for MLPH (or melanophilin) with 
8.2 and 1.7 down-regulation in HT144 and MM96L 
respectively. MLPH is known to bind directly to 
both RAB27A and MYO5A (miR-4731 target gene; 
Supplementary Table S4), all of which are considered 
integral components of melanosome transport [16].
Cell cycle pathway genes
According to Hanahan and Weinberg, the most 
fundamental trait of cancer cells is their inherent ability 
to sustain chronic proliferation which, in part, can be 
attributed to defects in the cell cycle [17]. In our dataset, 
we confirmed the strongest associated genes, present 
in 3/3 cell lines, were CCNA2, ORC5L, and PCNA 
(Supplementary Table S4). CCNA2 and PCNA have 
been identified as potential biomarkers for melanoma 
based upon a comprehensive assessment of publically 
available gene expression datasets [18]. Moreover, in a 
systematic review of melanoma immunohistochemical 
(IHC) and gene microarray studies, increased PCNA 
expression was consistently identified as being associated 
with worse clinical outcome in melanoma patients [19]. 
In 2/3 cell lines, BUB3, CDC45L, CDK4, and SKP1A 
were also found to be down-regulated. In total, 13/13 
genes were down-regulated in ≥1.3 fold in ≥1/3 cell lines 
(Supplementary Table S4). In the KEGG ‘cell cycle’ 
pathway shown in Figure 3, the miR-4731 target genes 
(red star) are represented at almost every critical stage of 
the cell cycle – indicating that the dysregulation of miR-
4731 could be critical to its regulation. A greater in depth 
analysis is therefore warranted to elucidate this hypothesis.
Oxidative phosphorylation genes
Oxidative phosphorylation is an important biological 
process. Recently, dysfunctional oxidative phosphorylation 
has been shown to be driven by the commonly mutated 
BRAF oncogene (V600E), allowing malignant melanoma 
cells to become addicted to glycolysis [20]. Subsequent 
qRT-PCR showed that 11/15 genes were down-regulated 
≥1.3 fold in ≥1/3 cell lines (Supplementary Table S4). 
However, given that the highest fold-change was -1.6, it 
is likely that miR-4731 regulation of the pathway is of a 
relatively minor nature.
The synovial sarcoma X breakpoint family is 
regulated by miR-4731
The synovial sarcoma X breakpoint family (SSX) is 
a cluster of cancer/testis (CT) antigens that have restricted 
expression in germ cells and is reactivated in tumours 
[21]. Given this selective expression, particularly in 
melanoma, it has long been suggested that they would be 
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prime candidates for immunotherapeutic treatment which 
has now recently been shown in vitro to have promising 
results [22]. SSX2 was the first to be identified as being 
expressed in melanoma tumours (50%) [23] and in a 
follow-up study Gure et al [24] discovered that the other 
SSX family members were also expressed at varying 
levels in both tumour and melanoma patient-derived 
serum. SSX expression has also been found to be an early 
event in melanocytic neoplasia with 2/24 naevi showing 
nuclear staining [25].
Indications that the SSX family members (SSX1-
4, SSX4B, and SSX5) were regulated by miR-4731 
can be observed in Supplementary Table S2, which 
shows that these genes were pulled down in 3/3 cell 
lines with fold changes ranging from 2.3 to 56.86. As 
a general rule, the fold change enrichment does not 
necessarily reflect the biological consequence of the 
binding of the biotinylated miRNA, however in these 
cases, all transcripts (except SSX5) were associated 
as being under transcriptional control of miR-4731. 
Importantly, knockdown of SSX4 and SSX4B by 
siRNAs has previously been shown to result in marked 
reduction (~50%) in 2D colony formation in SK-MEL-37 
melanoma cells [26]. Strikingly, cell proliferation and 
migration were unaffected by the lack of SSX4 or SSX4B 
expression [26]. Furthermore, in A375 cells, induction 
of SSX2 expression using a lentiviral construct (above 
endogenous tumour levels) led to a reduction of cell 
viability and colony formation, and induced cell cycle 
G1 checkpoint arrest [27]. SSX2 expression was further 
found to induce DNA damage response which promoted 
genomic instability [27]. The authors also showed that 
knockdown of SSX2 expression had a similar effect to 
the overexpressed constructs, with cell growth being 
diminished [27]. Therefore, based on these data, the 
authors concluded that melanoma appears dependent on 
an optimal level of SSX2 expression [27]. With these data 
in mind, we selected SSX4 as a representative of the SSX 
family for further investigation. In the same 3 melanoma 
cell lines, overexpression of miR-4731 mimic resulted 
in a 1.2-7.5 fold reduction of SSX4 protein expression 
relative to miR-NEG-scr (Figure 4a). In keeping with 
Figure 3: The ‘Cell Cycle’ KEGG pathway is represented with miR-4731 target genes (red stars). This highlights that 
miR-4731 has the potential to play a critical role in modulating cell cycle progression.
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previously published observations, knockdown of 
SSX4 via a siRNA pool showed a complete ablation of 
2D colony formation (Figure 4b–4c) in all 3 cell lines. 
Importantly, overexpression of miR-4731 mimic had the 
same effect on colony formation as SSX4 knockdown 
in HT144 and MM96L, with MM253 (Figure 4b–4c) 
showing a 1.7 fold decrease (~41% reduction), similar 
to the prior observation in SK-MEL-37 [26]. The lesser 
effect observed in MM253 matches the SSX4 protein 
expression (1.2 fold decrease) (Figure 4a). Interestingly, 
despite the dramatic reduction in 2D colony formation, 
there was no significant change in cell viability (data 
not shown). These data mirror the previous study by 
Caballero et al. [26] and strongly suggest that miR-4731 
modulates this via its regulation of SSX4. Although the 
caveat exists that the level of miR-4731 overexpression 
may be higher than that seen in vivo, we would argue 
that given the observed effect on the majority of the 
transcripts assessed, especially SSX4 at the protein 
level, that this level of overexpression, may in the future 
actually have therapeutic relevance – i.e. enhancing the 
tumour suppressive role of miR-4731. We therefore 
speculate that since the expression of miR-4731 decreases 
upon distal metastatic spread [2], it could be inferred 
that SSX4 protein levels would also increase, leading to 
enhanced tumour formation.
Conclusions
What is apparent from the GSEA of the pulled-
down miR-4731 target genes is that a single miRNA has 
the potential to have multiple effects, being involved in 
regulating genes involved in key pathways/processes 
related to melanocyte biology and/or melanoma. The 
identification of these enriched processes was enhanced 
by the use of high-throughput techniques such as 
the synthetic biotinylated miRNA-duplex pull-down 
procedure used here [6, 7] combined with an integrated 
network analysis programs such as STRING [12] which 
provided novel insights into our dataset. The validated 
pathways that we have highlighted, together with the 
commonly pulled down genes such as the SSX family, 
provide a significant insight into the role of miR-4731 
in melanomagenesis. In our previous publication [2], we 
found that the expression of miR-4731 was significantly 
lower in tissues derived from stage IV patients compared 
with stage III tissues. These data suggests that miR-4731 
may have a tumour suppressive function (with loss of 
a tumour suppressor being favourable to the metastatic 
tumour). Together with the functionally validated effect 
of miR-4731 on SSX4 protein expression, we have many 
other gene targets to bolster this notion. For example, the 
target gene CDK4, is well known as a potent oncogene 
in melanoma which is normally regulated via the tumour 
suppressor CDKN2A (p16). Upon overexpression of miR-
4731, we have shown that CDK4 expression levels are 
reduced in 2/3 cell lines which provide further support of 
miR-4731 having a tumour suppressive role. In the future, 
we may see melanoma-related miRNAs like miR-4731 
being used for therapeutic purposes – i.e. specifically 
targeted to melanoma with the aim of restoring 
miRNA levels, and in turn their interacting partners, 
to homeostasis. Finally, identification of target genes 
of ‘tissue-specific’ miRNAs like miR-4731 may allow 
a greater understanding of the tumourigenic process, 
unique to each cancer type. Armed with this knowledge, 
Figure 4: a. SSX4 expression is reduced following transient transfection of miR-4731-5p (miR-4731) mimic (5 nM) as compared to miR-
Neg-scr control. +/- indicates overexpression of the miR-4731 mimic (+) or miR-Neg-scr control (-). Numbers indicate relative fold change. 
SSX4 (~22 kDa) and GAPDH (~37 kDa) were run and quantified on the same gel. b. HT144, MM96L, and MM253 and were transiently 
transfected with 5 nM of siSSX4, miR-4731 mimic, and a negative control (miR-Neg-scr) with colonies stained with crystal violet 10-
14 days post transfection. This assay was repeated twice in triplicate and representative results are shown. c. Graphical representation of 
colony counts in replicate wells performed for each respective colony assay.
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we envisage that better tailored therapeutic options could 
be devised.
MATERIALS AND METHODS
Cell culture and total RNA extraction
All melanoma cell lines (Supplementary Table S1) 
have been previously described [1, 28, 29].
Cell lines were cultured in RPMI-1640 (#31800-089, 
Life Technologies, Foster City, CA, USA) supplemented 
with 10% fetal bovine serum (FBS) (Life Technologies), 
HEPES, 100 U/ ml penicillin and 100 μg/ml streptomycin 
(Life Technologies), and incubated at 37°C (5% CO
2
). 
All cell lines were periodically authenticated via short 
tandem repeat profiling according to the manufacturer’s 
instructions (AmpFISTR Profiler Plus ID kit; Life 
Technologies).
Cells were harvested from the plate and column-
purified using the miRNeasy Kit (QIAGEN, Hilden, 
Germany) according to the manufacturer’s instructions. 
Ethical approval for the study was granted by the QIMR 
Berghofer's Human Research Ethics Committee (HREC), 
approval number P1237.
miScript quantitative RT-PCR validation
Cell lines were reverse transcribed using miScript 
II RT Kits (QIAGEN) according to the manufacturer’s 
instructions. Real-time PCR was subsequently performed 
with a miScript SYBR Green PCR Kit (QIAGEN) 
using the 7900HT Fast Real Time PCR System (Life 
Technologies). Data were analysed in Microsoft Excel 
using the ΔCT method compared to RNU6 which was 
assessed in each sample. ΔCT values were plotted 
and statistical analysis performed in GraphPad Prism 
(v6.04).
Biotin pull-downs and microarray hybridizations 
and data analysis
Melanoma cell lines (MM96L, MM253 and 
HT144; all were BRAF V600E mutant positive) were 
selected based on their high transfection ability together 
with having endogenous miR-4731 expression. Synthetic 
biotinylated microRNA-duplexes were designed for miR-
4731 (Sequence 1: /5Phos/rUrGrCrUrGrGrGrGrGrCrCr
ArCrArUrGrArGrUrGrUrG/3Bio/ Sequence 2: /5Phos/rC
rArCrArCrArArGrUrGrGrCrCrCrCrCrArArCrArUrU) 
along with a scrambled control (Sequence 1: /5Phos/rUrA
rUrCrCrCrCrUrUrUrGrCrCrUrGrCrUrUrUrUrCrC/3Bio/ 
Sequence 2: /5Phos/rUrArArGrCrUrArGrArCrCrGrGrAr
GrGrArGrGrGrC) according to specifications detailed in 
the methodology devised by Cloonan and collegues [6, 7] 
(and optimised for melanoma cell lines [1]) and purchased 
from Integrated DNA Technologies (Coralville, USA). 
Microarray hybridizations were carried out as previously 
described (1).
In an effort to be inclusive, gene lists from each 
cell line were generated if the transcript occurred at an 
increased level (≥1.15 fold; ranged up to 51 fold) in the 
miR-4731 ‘pull-down’ as compared to the Neg-Scr. Next, 
each gene list was compared using a Venn diagram in 
GeneSpring GX 12.5 (Agilent Technologies) to identify 
overlapping transcripts. If a transcript was present in 3/3 
cell lines, it was carried forward into subsequent analysis 
(Supplementary Figure S1).
Network analysis
Transcripts present in 3/3 cell lines were used to 
identify relationships amongst each gene along with 
enrichment for key signalling pathways. First, obsolete 
accession numbers, identified using Batch Entrez (http://
www.ncbi.nlm.nih.gov/sites/batchentrez) were removed 
from the dataset as they were no longer associated with 
a bona fide gene. A list of unique gene names was then 
generated which could be imported into STRING v9.1 
(http://string-db.org/) which allowed for the identification 
and visualisation of known and predicted protein-protein 
interactions [12]. Enrichment for significant pathways 
(KEGG; http://www.kegg.jp/kegg/pathway.html) and GO 
terms (Gene Ontology; http://geneontology.org/) were 
also performed using STRING v9.1. False discovery rates 
(FDR) (i.e. corrected Bonferroni P-value) were applied 
against a genome-wide level, to the associated pathway.
microRNA target site prediction
All transcripts that were present in 3/3 cell lines were 
confirmed to be a potential target gene using the binding 
algorithm miRanda v3.3a [30] downloaded from http://
www.microrna.org/microrna/getDownloads.do (miRan 
da-Aug2010 version). FASTA formatted sequences were 
obtained for miR-4731 from miRBASE (http://www 
.mirbase.org/) and target genes were identified using a 
batch query from the NCBI (http://www.ncbi.nlm.nih 
.gov/sites/batchentrez). The program was run using default 
conditions with exceptions (binding threshold was set to 
100). TargetScan [31] (Release 6.2: June 2012), miRDB 
[32], TargetMiner [33], and DIANA-microT-CDS [34] 
predicted transcripts were identified via online databases 
and compared to miRanda v3.3a.
Criteria for selecting genes for qRT-PCR 
validation
First, the host gene of miR-4731, PMP22 was 
selected to confirm if it was under transcriptional 
control of miR-4731. It is important to note that PMP22 
was also a pull-down target in 3/3 cell lines. Second, 
all genes that had ≥2 fold enrichment in 3/3 cell lines 
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(n=37) were selected. Third following the input of the 
1092 unique Gene Names into STRING v9.1 (n=1076 
were identified and present in the database), gene set 
enrichment was performed (GSEA) for KEGG pathways 
(cell cycle and oxidative phosphorylation), and the gene 
ontology (GO) terms: ‘Biological Process’, ‘Molecular 
Function’, and ‘Cellular Components’ (melanosomes). 
Significant ‘pathways’ were selected based upon a priori 
relevance to melanoma and/or melanocyte biology. The 
significant pathways selected (‘cell cycle’, ‘oxidation 
phosphorylation’, and ‘melanosomes’) had further 
restrictions imposed in an attempt to be more stringent. 
i.e. all genes present in these pathways must have been 
pulled down in ≥1.5 fold, in ≥2/3 cell lines (n=43). In 
addition, considering the importance of the melanosome 
in melanomagenesis, we selected additional genes (not 
present in the pull-down) relevant to this the melanosome 
(FSCN1, MLPH, RAB27A, and TYR), to observe the effect 
of miR-4731 overexpression.
Transient transfection of miR-4731 mimic 
and negative scrambled control in melanoma 
cell lines
Transfection conditions have been previously 
described [1]. miR-4731-5p mimic (#MSY0019853), and 
Negative Allstars control (#1027280; miR-NEG-scr) were 
purchased from QIAGEN. A final concentration of 5 nM 
of mimic and negative control were reverse-transfected 
into MM96L, MM253 and HT144 (30,000 cells/6-well) 
using Lipofectamine® RNAiMAX (Life Technologies) 
and harvested for RNA at 72 h. RNA and protein was 
extracted as previously described [1]. Each biological 
sample was a pool of three transfected wells from a 6-well 
plate. Two independent experiments were performed.
Custom RT2 profiler PCR array
First, 400 ng of RNA from duplicate biological 
samples (individual transfections), underwent cDNA 
synthesis using the RT2 First Strand Kit (QIAGEN) 
followed by qRT-PCR using the RT2 SYBR® Green qPCR 
Mastermix (QIAGEN) and the Custom RT2 Profiler PCR 
Array (QIAGEN) which contained the pre-designed 
primer assays for all selected pull-down transcripts 
(n=83) (Supplementary Table S7). The parameters were 
as per manufacturer’s instructions. The array also had the 
endogenous controls HPRT1, RPLP0, ACTB (also a target 
of miR-4731), GAPDH, B2M and TFRC together with 
controls for assessing gDNA contamination and technical 
reproducibility (triplicate wells of reverse-transcription 
controls (RTC) and a positive PCR control (PPC)). 
These controls allow for testing of the PCR efficiency, 
with the replicates testing for inter-well, and intra-plate 
consistency. Each 384 well plate had duplicate samples for 
the overexpression of miR-4731 and the negative control 
(i.e. 4 biological samples per plate). Real-Time PCR was 
performed using the ViiA™ 7 Real-Time PCR System 
(Life Technologies) as per manufacturer’s instructions. 
CT values were extracted using ViiA™ 7 Software v1.2.4 
(Life Technologies) and analysed using the RT2 Profiler 
PCR Array Data Analysis software (QIAGEN).
Western blot and protein analysis
Samples (40 μg total protein) were resolved on 
4–15% Mini-PROTEAN TGX gels (Bio-Rad, Hercules, 
USA) and transferred to PVDF membranes using a Trans-
Blot®Turbo™ (Bio-Rad, Hercules, USA). The following 
antibodies were used to detect SSX4 (#ab172215; Abcam) 
and GAPDH (#2275-PC-100, R&D systems) at 1:1000 
and 1:5000 dilutions respectively along with a HRP-linked 
anti-mouse secondary at 1:10,000 (Thermo Fisher) or anti-
rabbit secondary at 1:7500 (Merck Millipore). Enhanced 
chemiluminescence (ECL) detection of antibody binding 
was quantified using the C-Digit scanner and Image Studio 
software (Licor).
2D Colony assays
Melanoma cell lines (MM96L, MM253, and 
HT144) were reverse transfected with a SSX4 siRNA 
(siSSX4; # 1027416, siRNA #4, FlexiTube GeneSolution 
GS6759), a miR-4731-5p mimic (#MSY0019853), and 
a Negative Allstars control (#1027280; miR-NEG-scr) 
purchased from QIAGEN as described and seeded at a 
density of 1000 cells/well into a 6-well plate. Colonies 
were stained with crystal violet 10-14 days post 
transfection using standard methodology. Triplicate wells 
for each transfection were performed in two independent 
experiments. Colonies were counted using Clono-Counter 
software [35].
Cell viability assays
Cell viability assays were performed and determined 
using a modified sulforhodamine B (SRB; Sigma, St 
Louis, USA) assay [36]. Briefly, miRNA mimic and miR-
NEG-scr were reverse-transfected with melanoma cell 
lines and seeded into a 96-well plate (6 wells/transfection) 
then incubated at 37ºC with 5% CO2 for 96 h. Plates were 
fixed on day 4 with methylated spirits prior to performing 
the SRB assay and read at 564 nm using a plate reader 
(Molecular Devices, Sunnyvale, USA). Each experiment 
(6 wells) was performed in duplicate using independent 
transfections.
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